Evidence map›Paper›PMID 34017245›Full record

ArticleFrontiers in pharmacology2020

Integrated Random Negative Sampling and Uncertainty Sampling in Active Learning Improve Clinical Drug Safety Drug-Drug Interaction Information Retrieval.

Weixin Xie, Limei Wang, Qi Cheng, Xueying Wang, Ying Wang, Hongyuan Bi, Bo He, Weixing Feng

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weixin XieInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Limei WangInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Qi ChengInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Xueying WangInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Ying WangInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Hongyuan BiThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Bo HeInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Weixing FengInstitute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical drug-drug interactions (DDIs) have been a major cause for not only medical error but also adverse drug events (ADEs). The published literature on DDI clinical toxicity continues to grow significantly, and high-performance DDI information retrieval (IR) text mining methods are in high demand. The effectiveness of IR and its machine learning (ML) algorithm depends on the availability of a large amount of training and validation data that have been manually reviewed and annotated. In this study, we investigated how active learning (AL) might improve ML performance in clinical safety DDI IR analysis. We recognized that a direct application of AL would not address several primary challenges in DDI IR from the literature. For instance, the vast majority of abstracts in PubMed will be negative, existing positive and negative labeled samples do not represent the general sample distributions, and potentially biased samples may arise during uncertainty sampling in an AL algorithm. Therefore, we developed several novel sampling and ML schemes to improve AL performance in DDI IR analysis. In particular, random negative sampling was added as a part of AL since it has no expanse in the manual data label. We also used two ML algorithms in an AL process to differentiate random negative samples from manually labeled negative samples, and updated both the training and validation samples during the AL process to avoid or reduce biased sampling. Two supervised ML algorithms, support vector machine (SVM) and logistic regression (LR), were used to investigate the consistency of our proposed AL algorithm. Because the ultimate goal of clinical safety DDI IR is to retrieve all DDI toxicity-relevant abstracts, a recall rate of 0.99 was set in developing the AL methods. When we used our newly proposed AL method with SVM, the precision in differentiating the positive samples from manually labeled negative samples improved from 0.45 in the first round to 0.83 in the second round, and the precision in differentiating the positive samples from random negative samples improved from 0.70 to 0.82 in the first and second rounds, respectively. When our proposed AL method was used with LR, the improvements in precision followed a similar trend. However, the other AL algorithms tested did not show improved precision largely because of biased samples caused by the uncertainty sampling or differences between training and validation data sets.

Indexed as

active learning (AL)drug–drug interaction (DDI)information retrieval (IR)random negative samplingtext mining (TM)

Identifiers

PMID34017245
PMCPMC8130007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.